The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Strategies to improve lung cancer outcomes
Following the annual National Lung Cancer Audit (NCLA) report, the pandemic exacerbated the challenges clinicians face in proving adequate lung cancer care. Neal Navani, MA, MRCP, MSc, PhD, Care Quality Improvement Department, Royal College of Physicians, London, UK, comments on what needs to be done to optimize lung cancer outcomes in patients. Reestablishment of initiatives such as low dosage CT screening programs have shown to reduce mortality, and awareness campaigns can increase diagnosis rates among symptomatic patients. However, further work is needed to reduce emergency presentations of lung cancer. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Dr Navani has received honoraria for speaking, advisory boards or travel support from Amgen, Aidence, Astra Zeneca, Lilly, Takeda, Janssen, Merck, MSD, Pfizer, Oncimmune, PeerVoice, OncLive, Bristol-Meyers-Squibb and Olympus, as well as educational grants from Olympus, Cook Medical, Hitachi and Pentax.
